Reading this on a mobile device? Try our optimized mobile version here:

October 1, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenge's faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio.
  Health Care & Policy 
  • Aveo submits kidney cancer drug tivozanib for FDA approval
    Aveo Oncology filed with the FDA a new-drug application for kidney cancer treatment tivozanib. The filing is based on a study involving 517 patients with advanced renal cell carcinoma who didn't undergo systemic therapy. The drug is co-developed by Astellas Pharma. Boston Herald (9/28) LinkedInFacebookTwitterEmail this Story
  • Ariad lung cancer treatment shows promise in Phase I/II trial
    A Phase I/II study found that Ariad Pharmaceuticals' investigational drug AP26113 reduced tumor size in eight of 11 patients with nonsmall-cell lung cancer who carry a mutation in the ALK gene. Ariad plans to initiate a midstage trial before year-end. Reuters (9/29) LinkedInFacebookTwitterEmail this Story
  • Repligen's muscular atrophy drug enters early-stage development
    Repligen initiated a trial to assess the safety and pharmacokinetics of RG3039, an experimental drug for spinal muscular atrophy. The Phase Ib study will involve 32 adult healthy volunteers. "Completion of this stage of the RG3039 clinical development program in healthy volunteers, if successful, will provide the necessary foundation for more advanced trials involving SMA patients who are in critical need of a treatment for this devastating disease," Repligen president and CEO Walter Herlihy said. Pharmaceutical Business Review Online (9/28) LinkedInFacebookTwitterEmail this Story
  • Method could reduce tumor potential of iPS cell therapies
    Mayo Clinic researchers treated induced pluripotent stem cells with a chemotherapy drug to selectively kill the cells that can trigger tumors. The method may make treatments using the cells more effective and safer, according to the study published in the journal Stem Cells Translational Medicine. Medical News Today (9/28) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  • Bayer CropScience to put $9 billion toward driving growth
    Bayer CropScience could invest about $6.5 billion on research and development and an additional $2.5 billion in new production capacity and seed processing plants through 2016 as part of its growth strategy, Bayer CEO Sandra Peterson said. "Bayer CropScience aims to lead the way in sustainable crop solutions, and we are heavily investing in R&D, as well as production capacities, to respond to global demand for differentiated crop solutions," Peterson said. Farm Futures (9/25) LinkedInFacebookTwitterEmail this Story
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • An ethanol waiver would undermine support for all biofuels, exec says
    Renewable Energy Group, the biggest producer of biodiesel in the U.S., called on the Environmental Protection Agency to reject calls for a temporary suspension of the ethanol portion of the Renewable Fuel Standard. An RFS waiver would weaken investor confidence in all biofuels and may even push up retail food costs, said REG President and CEO Daniel Oh. "Food is more available because biofuels have increased overall agricultural production," Oh said. AOL Energy (9/30) LinkedInFacebookTwitterEmail this Story
First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events.
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Inspiration exists, but it has to find us working."
--Pablo Picasso,
Spanish artist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information